MSH2 and neoplasm: In the study by Remo et al (7), all neoplastic cells were observed to express hMSH2 protein but were negative for hMLH1; a BRAF V600E mutation was identified, but no KRAS mutation was present, which is consistent with the study by Pancione et al. Remo et al (7) also reported that the promoter regions of the characteristic subset of genes for the CIMP status (NEUROG1, IGF2, RUNX3, SOCS1, including MLH1) were hypermethylated, suggesting the presence of a CIMP+ and MSI-high tumor.